

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2007/061850

A. CLASSIFICATION OF SUBJECT MATTER

A61K45/00(2006.01)i, A61K39/395(2006.01)i, A61P7/06(2006.01)i, A61P35/02(2006.01)i, A61P43/00(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 Minimum documentation searched (classification system followed by classification symbols)
 A61K45/00, A61K39/395, A61P7/06, A61P35/02, A61P43/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

 Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2007
 Kokai Jitsuyo Shinan Koho 1971-2007 Toroku Jitsuyo Shinan Koho 1994-2007

 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 BIOSIS (STN), CAPplus (STN), EMBASE (STN), MEDLINE (STN), WPI (DIALOG),
 JMEDPlus (JDream2), JST7580 (JDream2), JSTPlus (JDream2)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 10-510842 A (ZymoGenetics, Inc.), 20 October, 1998 (20.10.98), Claims; page 8, lines 21 to 24; examples & WO 96/40218 A1 & AU 199662500 A & EP 831888 A1 & US 6013067 A & MX 199709244 A1 & KR 1999022420 A & CN 1190348 A	1-11, 18, 19, 21-23
X	JP 2005-539082 A (Ortho-Mcneil Pharmaceutical Inc.), 22 December, 2005 (22.12.05), Full text & WO 2004/026332 A1 & AU 2003275077 A1 & EP 1542714 A1 & NO 200501841 A & BR 200314591 A & US 2005/0282277 A1 & CN 1723036 A & ZA 200503036 A & KR 2005093759 A	1-11, 18-20, 22, 23

 Further documents are listed in the continuation of Box C.

 See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

 Date of the actual completion of the international search
 24 July, 2007 (24.07.07)

 Date of mailing of the international search report
 07 August, 2007 (07.08.07)

 Name and mailing address of the ISA/
 Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2007/061850

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAKAMURA, T., <i>et al.</i> , A Novel Non-Peptidyl Human C-Mpl Agonist, NIP-004, Stimulates Human Megakaryopoiesis and Thrombopoiesis [online]. Blood (ASH Annual Meeting Abstracts), 2005, 106: Abstract 3148. Retrieved from the Internet: <URL: http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;106/11/3148?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=NIP-004&searchid=1&FIRSTINDEX=0&volume=106&issue=11&resourcetype=HWCIT >, full text	1,18 2-11,19-23
Y	SUZUKI, K., <i>et al.</i> , YM477, a Novel Orally-Active Thrombopoietin Receptor Agonist [online]. Blood (ASH Annual Meeting Abstracts), 2005, 106: Abstract 2298. Retrieved from the Internet: <URL: http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;106/11/2298?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=YM477&searchid=1&FIRSTINDEX=0&volume=106&issue=11&resourcetype=HWCIT >, full text	1,18 2-11,19-23
Y	WO 2005/107784 A1 (Chugai Pharmaceutical Co., Ltd.), 17 November, 2005 (17.11.05), Claims; abstract (Family: none)	1-11,18-23
Y	WO 2005/056604 A1 (Chugai Pharmaceutical Co., Ltd.), 23 June, 2005 (23.06.05), Claims; abstract & EP 1616881 A1 & NO 200603224 A & US 2006/0222643 A1 & AU 2004297111 A1 & MX 2006006289 A1 & BR 200417077 A & KR 2006107572 A	1-11,18-23
Y	WO 02/33072 A1 (Chugai Pharmaceutical Co., Ltd.), 25 April, 2002 (25.04.02), Claims; abstract & AU 200210917 A & EP 1327680 A1 & KR 2003055274 A & CN 1469925 A & US 2004/0091475 A1 & CN 1721445 A	1-11,18-23
A	JP 2004-222502 A (Asahi Kasei Corp.), 12 August, 2004 (12.08.04), (Family: none)	1-11,18-23
A	JP 2005-204539 A (Mitsubishi Pharma Corp.), 04 August, 2005 (04.08.05), & WO 2005/071064 A1	1-11,18-23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2007/061850

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 12-17

because they relate to subject matter not required to be searched by this Authority, namely:

The invention according to claims 12-17 includes the step of administering an agonist for TPO receptor to a test subject, and corresponds to a method for treatment of the human body by therapy because the human is included in the test subject. (PCT Article 17(2)(a)(i), PCT Rule 39.1(iv))

2. Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest
the

The additional search fees were accompanied by the applicant's protest and, where applicable, payment of a protest fee..

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2007/061850

Regarding claims 1-11, 18-23

Claims 1-11, 18-23 describe an agonist for TPO receptor as an active ingredient of a drug or an ingredient to be used for manufacturing a drug.

As the agonist for TPO receptor, a lot of compounds other than TPO can be included, however, even a person skilled in the art cannot clearly realize the whole compounds. Further, even if the description of the specification is examined, it is not described to such an extent that the whole compounds are made clear.

Thus, a sufficient support by the specification is not made by the description of the claims. Further, it is not clearly and sufficiently disclosed to such an extent that a person skilled in the art can make implementation. (PCT Articles 5 and 6)

Incidentally, in the creation of this international search report, a prior art search was carried out based on the description of the specification within a reasonable range.